In fact, a 2019 UK cost-effectiveness study of patients with newly diagnosed ALL demonstrated that the costs of first-line lyophilized pegaspargase were lower compared with L-asparaginase and were associated with more quality-adjusted life year gains [23]. Here, ASPG is linked to acute lymphoblastic leukemia.